MedTrace Logo

Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects

NCT04504760 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-05-03

No results posted yet for this study

Summary

To investigate safety, tolerability and pharmacokinetics in Japanese and Caucasian subjects when ONO-2910 is administered as single and multiple doses orally.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ONO-2910

Single ascending dose of ONO-2910 will be administered orally.

DRUG

Placebo

Single dose of placebo will be administered orally.

DRUG

ONO-2910

Multiple ascending dose of ONO-2910 will be administered orally.

DRUG

Placebo

Multiple dose of placebo will be administered orally.

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Masaharu Komeno · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2021-03-18
Completion
2021-03-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504760 on ClinicalTrials.gov